Ensign Peak Advisors Inc Acquires 1,800 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Ensign Peak Advisors Inc raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 15.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,550 shares of the company’s stock after buying an additional 1,800 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Vera Therapeutics were worth $573,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Avoro Capital Advisors LLC grew its stake in Vera Therapeutics by 30.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock valued at $237,247,000 after acquiring an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Vera Therapeutics by 11.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock worth $185,107,000 after acquiring an additional 437,940 shares in the last quarter. FMR LLC increased its stake in Vera Therapeutics by 9.6% during the fourth quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after acquiring an additional 267,842 shares during the last quarter. Vanguard Group Inc. increased its stake in Vera Therapeutics by 14.3% during the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after acquiring an additional 369,387 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Vera Therapeutics by 43.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,415,179 shares of the company’s stock worth $59,848,000 after purchasing an additional 431,178 shares during the period. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

VERA has been the subject of a number of analyst reports. Guggenheim raised their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research note on Tuesday, March 4th. HC Wainwright started coverage on Vera Therapeutics in a research report on Monday, May 5th. They set a “buy” rating and a $75.00 target price on the stock. Finally, Wedbush dropped their target price on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $63.33.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $21.25 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock’s fifty day moving average is $23.49 and its two-hundred day moving average is $34.01. The firm has a market capitalization of $1.35 billion, a P/E ratio of -8.14 and a beta of 1.28. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business posted ($0.56) earnings per share. On average, research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.